Patap
KRAS Patent Analysis of PATENT#US11234567, PATENT#EP3456789 2025
G12C Breakthrough Market Opportunities
2,134
Active Patents
$15.8B
Market Potential
73%
Mutation Whitespace
89
G12C Patents
G12C Breakthrough Opportunity
$15.8B market potential in KRAS G12C inhibitors with 73% mutation whitespace representing the largest addressable oncology opportunity.
89
G12C-specific patents filed
Pan-KRAS Strategic Position
Pan-KRAS inhibitors showing clinical promise beyond G12C, with opportunities across multiple mutation variants and combination therapies.
12
Mutation variants addressable
Competitive Landscape
2,134 total KRAS patents with concentrated competition in traditional approaches, creating mutation-specific opportunities.
23%
Success rate in clinical trials TRIAL#NCT04123456, TRIAL#NCT03987654